Immune OTC Stock Today

IMUN -  USA Stock  

USD 2.30  0.60  20.69%

Immune Therapeutics is selling for 2.30 as of the 22nd of October 2021. This is a -20.69 percent decrease since the beginning of the trading day. The stock's open price was 2.9. Immune Therapeutics has 51 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Immune Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of September 2021 and ending today, the 22nd of October 2021. Click here to learn more.
 Market Performance
1 of 100
  Odds Of Distress
Over 51
Immune Therapeutics, Inc. focuses on the development, approval, and commercialization of pharmaceutical products. Immune Therapeutics, Inc. was incorporated in 1993 and is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.. The company has 481.91 K outstanding shares. More on Immune Therapeutics
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Immune Therapeutics OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Immune Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Immune Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Immune Therapeutics has very high historical volatility over the last 90 days
Immune Therapeutics has high likelihood to experience some financial distress in the next 2 years
Immune Therapeutics currently holds about 11.66 K in cash with (191.5 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Roughly 17.0% of the company shares are held by company insiders
Latest headline from MiNK Therapeutics Announces Closing of Initial Public Offering - KULR-TV
Legal NameImmune Therapeutics
ChairmanNicholas Plotnikoff  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Immune Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Immune Therapeutics [IMUN] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Nano-Cap' category with current market capitalization of 1.35 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immune Therapeutics's market, we take the total number of its shares issued and multiply it by Immune Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Immune Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 481.91 K outstanding shares. Immune Therapeutics currently holds about 11.66 K in cash with (191.5 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Check Immune Therapeutics Probability Of Bankruptcy
Immune Therapeutics retains 17.25 (percent) if its outstanding shares held by insiders and 17.25 (percent) owned by outside corporations .

Ownership Allocation (%)

Check Immune Ownership Details

Immune Stock Price Odds Analysis

What are Immune Therapeutics' target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Immune Therapeutics jumping above the current price in 90 days from now is roughly 96.0%. The Immune Therapeutics probability density function shows the probability of Immune Therapeutics otc stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the otc stock has a beta coefficient of 1.0736. This usually indicates Immune Therapeutics market returns are very sensitive to returns on the market. As the market goes up or down, Immune Therapeutics is expected to follow. Additionally, the company has an alpha of 0.0492, implying that it can generate a 0.0492 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 2.3HorizonTargetOdds Up 2.3 
3.57%90 days
Based on a normal probability distribution, the odds of Immune Therapeutics to move above the current price in 90 days from now is roughly 96.0 (This Immune Therapeutics probability density function shows the probability of Immune OTC Stock to fall within a particular range of prices over 90 days) .

Immune Therapeutics Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Immune Therapeutics market risk premium is the additional return an investor will receive from holding Immune Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Immune Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Immune Therapeutics' alpha and beta are two of the key measurements used to evaluate Immune Therapeutics' performance over the market, the standard measures of volatility play an important role as well.

Immune Stock Against Markets

Picking the right benchmark for Immune Therapeutics otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Immune Therapeutics otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Immune Therapeutics is critical whether you are bullish or bearish towards Immune Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immune Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now


Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Immune Therapeutics Corporate Directors

Immune Therapeutics corporate directors refer to members of an Immune Therapeutics board of directors. The board of directors generally takes responsibility for the Immune Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Immune Therapeutics' board members must vote for the resolution. The Immune Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Jack Brewer - DirectorProfile
Clifford Selsky - Independent DirectorProfile
Kevin Phelps - DirectorProfile
Edward Teraskiewicz - Independent DirectorProfile
Please see Risk vs Return Analysis. Note that the Immune Therapeutics information on this page should be used as a complementary analysis to other Immune Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Immune OTC Stock analysis

When running Immune Therapeutics price analysis, check to measure Immune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immune Therapeutics is operating at the current time. Most of Immune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Immune Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immune Therapeutics' price. Additionally, you may evaluate how the addition of Immune Therapeutics to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
The market value of Immune Therapeutics is measured differently than its book value, which is the value of Immune that is recorded on the company's balance sheet. Investors also form their own opinion of Immune Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immune Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immune Therapeutics' market value can be influenced by many factors that don't directly affect Immune Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immune Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immune Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immune Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.